BOSTON, April 5 /PRNewswire/ -- Monster scorpions. Bulging muscles. Passionate kisses. The clash begins this week -- Clash of the Titans that is.

CAMBRIDGE, Mass., Feb.

Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue.

The acquisition of Protez will see Novartis gain US and EU rights to the pipeline antibiotic PZ-601, a novel broad-spectrum carbapenem in Phase II development for the treatment of drug-resistant infections, including MRSA.

-- Data show Novartis Meningitis B (MenB) vaccine has potential to be first vaccine to provide broad protection to infants against meningococcal B infections -- The meningococcal B strain causes 72% of meningococcal disease in Europe and is a major cause of the disease in other regions of the world -- Novartis MenB vaccine and Novartis Menveo(R) (MenACWY-CRM) vaccine on track to establish strong portfolio of meningitis vaccines New data for the investigational recombinant meningococcal group B vaccine developed by Novartis Vaccines, support its promise as the first potentially broad coverage vaccine capable of protecting infants against the meningococcal B strain.